Zika Virus as Oncolytic Therapy for Brain Cancer: Myth or Reality?

Area of Science:

• Virology
• Oncology
• Neuroscience

Background:

• Oncolytic viruses (OVs) are a promising cancer therapy, selectively targeting and destroying cancer cells while stimulating anti-tumor immunity.
• Zika virus (ZIKV), known for its global health impact, has emerged as a potential oncolytic agent, particularly for glioblastoma multiforme (GBM).
• GBM is the most common and aggressive primary brain tumor, characterized by a poor prognosis and limited treatment options.

Purpose of the Study:

• To evaluate the oncolytic potential of Zika virus (ZIKV) for treating glioblastoma multiforme (GBM).
• To investigate the neurotropism of ZIKV in relation to GBM-specific molecular targets.
• To explore genetic modifications for enhancing ZIKV's safety and efficacy as an oncolytic virus.

Main Methods:

• Assessing ZIKV neurotropism in the context of GBM.
• Evaluating ZIKV's interaction with receptor tyrosine kinase AXL, its ligand Gas6, and RNA-binding protein Musashi-1 (MSI1).
• Reviewing genetic modifications aimed at improving ZIKV's therapeutic profile.

Main Results:

• ZIKV demonstrates oncolytic potential against GBM.
• The virus's entry and replication mechanisms are linked to GBM-associated molecules AXL and MSI1.
• GBM overexpresses AXL, Gas6, and MSI1, indicating ZIKV's potential for tumor-specific targeting.

Conclusions:

• Zika virus exhibits promising oncolytic activity against glioblastoma.
• The virus's tropism for GBM, mediated by AXL and MSI1, supports its potential as a targeted cancer therapeutic.
• Further research into genetically modified ZIKV strains could advance oncolytic virus therapy for brain tumors.